$1.19 Billion is the total value of Logos Global Management LP's 58 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 62.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXO | ALX ONCOLOGY HLDGS INC | $172,624,000 | -25.8% | 3,156,981 | 0.0% | 14.51% | -36.1% | |
| OLMA | OLEMA PHARMACEUTICALS INC | $104,754,000 | -15.7% | 3,743,875 | 0.0% | 8.80% | -27.4% | |
| DSGN | DESIGN THERAPEUTICS INC | $54,349,000 | -33.5% | 2,732,501 | 0.0% | 4.57% | -42.7% | |
| VERV | New | VERVE THERAPEUTICS INC | $45,685,000 | – | 758,265 | +100.0% | 3.84% | – |
| DYN | Sell | DYNE THERAPEUTICS INC | $43,224,000 | -13.1% | 2,054,392 | -35.9% | 3.63% | -25.2% |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $40,271,000 | +1348.6% | 1,100,000 | +1674.2% | 3.38% | +1148.7% |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $37,047,000 | +54.1% | 325,000 | +62.5% | 3.11% | +32.7% |
| GRPH | New | GRAPHITE BIO INC | $32,905,000 | – | 1,070,762 | +100.0% | 2.76% | – |
| TIL | Sell | INSTIL BIO INC | $32,783,000 | -29.2% | 1,696,850 | -8.1% | 2.76% | -39.0% |
| CMPS | Buy | COMPASS PATHWAYS PLCsponsored ads | $32,428,000 | +252.3% | 850,000 | +240.0% | 2.72% | +203.5% |
| NKTX | Sell | NKARTA INC | $31,765,000 | -23.4% | 1,002,382 | -20.5% | 2.67% | -34.0% |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $31,208,000 | +135.7% | 400,000 | +185.7% | 2.62% | +103.0% |
| KNTE | Buy | KINNATE BIOPHARMA INC | $30,953,000 | +6.3% | 1,329,602 | +42.3% | 2.60% | -8.5% |
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $30,241,000 | -23.5% | 1,215,000 | -13.8% | 2.54% | -34.1% |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $29,273,000 | – | 1,125,000 | +100.0% | 2.46% | – |
| IPSC | New | CENTURY THERAPEUTICS INC | $29,020,000 | – | 989,095 | +100.0% | 2.44% | – |
| CYTK | Buy | CYTOKINETICS INC | $27,706,000 | +70.2% | 1,400,000 | +100.0% | 2.33% | +46.5% |
| EWTX | Buy | EDGEWISE THERAPEUTICS INC | $26,275,000 | -23.5% | 1,231,812 | +16.6% | 2.21% | -34.1% |
| RAPT | New | RAPT THERAPEUTICS INCcall | $23,843,000 | – | 750,000 | +100.0% | 2.00% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $22,120,000 | – | 350,000 | +100.0% | 1.86% | – |
| BCYC | Sell | BICYCLE THERAPEUTICS PLCsponsored ads | $21,707,000 | -9.2% | 715,000 | -10.6% | 1.82% | -21.8% |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $20,867,000 | – | 939,545 | +100.0% | 1.75% | – |
| BMEA | New | BIOMEA FUSION INC | $18,144,000 | – | 1,162,320 | +100.0% | 1.52% | – |
| ISEE | Buy | IVERIC BIO INC | $15,775,000 | +112.7% | 2,500,000 | +108.3% | 1.33% | +83.1% |
| GHRS | New | GH RESEARCH PLCordinary shares | $15,740,000 | – | 724,333 | +100.0% | 1.32% | – |
| ATHA | Buy | ATHIRA PHARMA INC | $14,447,000 | -22.3% | 1,410,812 | +39.6% | 1.21% | -33.1% |
| JANX | New | JANUX THERAPEUTICS INC | $13,651,000 | – | 547,122 | +100.0% | 1.15% | – |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $12,489,000 | +161.9% | 2,300,000 | +187.5% | 1.05% | +125.8% |
| RAIN | New | RAIN THERAPEUTICS INC | $12,126,000 | – | 780,331 | +100.0% | 1.02% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $11,853,000 | – | 675,000 | +100.0% | 1.00% | – |
| COGT | COGENT BIOSCIENCES INC | $11,520,000 | -7.6% | 1,420,500 | 0.0% | 0.97% | -20.5% | |
| PRLD | New | PRELUDE THERAPEUTICS INC | $11,452,000 | – | 400,000 | +100.0% | 0.96% | – |
| KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $11,144,000 | +50.5% | 800,000 | +100.0% | 0.94% | +29.6% |
| HARP | Buy | HARPOON THERAPEUTICS INC | $11,096,000 | +76.8% | 800,000 | +166.7% | 0.93% | +52.5% |
| ELDN | Buy | ELEDON PHARMACEUTICALS INC | $10,598,000 | +342.0% | 1,339,793 | +497.9% | 0.89% | +280.8% |
| LABP | Buy | LANDOS BIOPHARMA INC | $10,385,000 | +46.9% | 899,106 | +22.5% | 0.87% | +26.5% |
| RPTX | Sell | REPARE THERAPEUTICS INC | $10,289,000 | -62.7% | 330,000 | -63.3% | 0.86% | -67.9% |
| RAPT | New | RAPT THERAPEUTICS INC | $8,583,000 | – | 270,000 | +100.0% | 0.72% | – |
| TALS | New | TALARIS THERAPEUTICS INC | $7,461,000 | – | 507,923 | +100.0% | 0.63% | – |
| CGEM | Sell | CULLINAN ONCOLOGY INC | $7,428,000 | -56.9% | 288,458 | -30.2% | 0.62% | -62.9% |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $7,056,000 | +7.3% | 206,564 | +3.3% | 0.59% | -7.6% |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $6,810,000 | – | 300,000 | +100.0% | 0.57% | – |
| New | CATABASIS PHARMACEUTICALS IN | $6,731,000 | – | 3,190,000 | +100.0% | 0.57% | – | |
| ASLN | Sell | ASLAN PHARMACEUTICALS LTDads | $6,600,000 | -14.3% | 2,000,000 | -13.0% | 0.56% | -26.2% |
| ALGS | Sell | ALIGOS THERAPEUTICS INC | $4,339,000 | -60.0% | 212,785 | -55.3% | 0.36% | -65.5% |
| CCCC | C4 THERAPEUTICS INC | $4,273,000 | +2.3% | 112,928 | 0.0% | 0.36% | -12.0% | |
| IKNA | Sell | IKENA ONCOLOGY INC | $4,210,000 | -64.5% | 299,853 | -28.6% | 0.35% | -69.4% |
| ANNX | ANNEXON INC | $3,593,000 | -19.1% | 159,622 | 0.0% | 0.30% | -30.4% | |
| BCTG | BCTG ACQUISITION CORP | $2,276,000 | +2.3% | 200,000 | 0.0% | 0.19% | -12.0% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $2,144,000 | +2.3% | 200,000 | 0.0% | 0.18% | -11.8% | |
| PASG | PASSAGE BIO INC | $1,655,000 | -24.3% | 125,010 | 0.0% | 0.14% | -34.7% | |
| FSII | Sell | FS DEVELOPMENT CORP II | $1,233,000 | -58.7% | 123,543 | -58.8% | 0.10% | -64.4% |
| HSAQ | Sell | HEALTH SCIENCES ACQ CORP 2 | $1,020,000 | -69.6% | 100,000 | -66.7% | 0.09% | -73.8% |
| RACB | Sell | RESEARCH ALLIANCE CORP II | $1,014,000 | -67.0% | 100,000 | -66.7% | 0.08% | -71.7% |
| DAWN | New | DAY ONE BIOPHARMACEUTICALS I | $844,000 | – | 37,069 | +100.0% | 0.07% | – |
| HLXA | Sell | HELIX ACQUISITION CORP | $518,000 | -74.6% | 50,000 | -75.0% | 0.04% | -77.9% |
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $173,000 | -2.8% | 66,666 | 0.0% | 0.02% | -11.8% | |
| MREO | New | MEREO BIOPHARMA GROUP PLCads | $149,000 | – | 46,984 | +100.0% | 0.01% | – |
| CEREW | Exit | CEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202 | $0 | – | -33,333 | -100.0% | -0.01% | – |
| EAR | Exit | EARGO INC | $0 | – | -50,000 | -100.0% | -0.24% | – |
| CNTB | Exit | CONNECT BIOPHARMA HLDGS LTDads | $0 | – | -150,000 | -100.0% | -0.27% | – |
| LHDX | Exit | LUCIRA HEALTH INC | $0 | – | -250,000 | -100.0% | -0.30% | – |
| HRMY | Exit | HARMONY BIOSCIENCES HLDGS IN | $0 | – | -100,000 | -100.0% | -0.32% | – |
| LRMR | Exit | LARIMAR THERAPEUTICS INC | $0 | – | -230,000 | -100.0% | -0.33% | – |
| VIRX | Exit | VIRACTA THERAPEUTICS INC | $0 | – | -470,000 | -100.0% | -0.42% | – |
| BOLT | Exit | BOLT BIOTHERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.48% | – |
| RACA | Exit | THERAPEUTICS ACQUISITION COR | $0 | – | -500,000 | -100.0% | -0.51% | – |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -125,000 | -100.0% | -0.53% | – |
| VRDN | Exit | VIRIDIAN THERAPEUTICS INC | $0 | – | -550,000 | -100.0% | -0.90% | – |
| VINC | Exit | VINCERX PHARMA INC | $0 | – | -480,000 | -100.0% | -0.90% | – |
| KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -260,920 | -100.0% | -0.99% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INC | $0 | – | -400,000 | -100.0% | -1.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-08-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.